{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:05:20Z","timestamp":1761973520578,"version":"build-2065373602"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T00:00:00Z","timestamp":1368662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40268-013-0016-6","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T12:53:44Z","timestamp":1368622424000},"page":"137-143","source":"Crossref","is-referenced-by-count":2,"title":["Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects"],"prefix":"10.1007","volume":"13","author":[{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"first","affiliation":[]},{"given":"Ricardo","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,5,16]]},"reference":[{"issue":"14","key":"16_CR1","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","volume":"42","author":"J Benes","year":"1999","unstructured":"Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem. 1999;42(14):2582\u20137.","journal-title":"J Med Chem"},{"issue":"2\u20133","key":"16_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","volume":"44","author":"D Hainzl","year":"2001","unstructured":"Hainzl D, Parada A, Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res. 2001;44(2\u20133):197\u2013206.","journal-title":"Epilepsy Res"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/9781444316667.ch38","volume-title":"The treatment of epilepsy","author":"L Almeida","year":"2009","unstructured":"Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon S, Perucca E, Engel J, editors. The treatment of epilepsy. 3rd ed. Oxford: Blackwell Publishing; 2009. p. 485\u201398.","edition":"3"},{"issue":"6","key":"16_CR4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935\u201346.","journal-title":"Epilepsia"},{"issue":"5","key":"16_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","volume":"28","author":"A Falcao","year":"2007","unstructured":"Falcao A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2\u2013093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos. 2007;28(5):249\u201356.","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"16_CR6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","volume":"64","author":"L Almeida","year":"2008","unstructured":"Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267\u201373.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"16_CR7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/0091270008319706","volume":"48","author":"L Almeida","year":"2008","unstructured":"Almeida L, Minciu I, Nunes T, Butoianu N, Falcao A, Magureanu SA, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol. 2008;48(8):966\u201377.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"16_CR8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","volume":"46","author":"J Maia","year":"2008","unstructured":"Maia J, Almeida L, Falc\u00e3o A, Soares E, Mota F, Potgieter JH, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008;46(3):119\u201330.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1\u20132","key":"16_CR9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","volume":"96","author":"E Perucca","year":"2011","unstructured":"Perucca E, Elger C, Halasz P, Falcao A, Almeida L, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res. 2011;96(1\u20132):132\u20139.","journal-title":"Epilepsy Res"},{"issue":"Suppl. 6","key":"16_CR10","first-page":"118","volume":"52","author":"N Pires","year":"2011","unstructured":"Pires N, Palma N, Loureiro AI, Bonifacio MJ, Wright LC, Soares-da-Silva P. Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the maximal electroconvulsive shock test in the mice. Epilepsia. 2011;52(Suppl. 6):118.","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"16_CR11","first-page":"118","volume":"52","author":"L Torrao","year":"2011","unstructured":"Torrao L, Machado R, Pires N, Palma N, Bonifacio MJ, Wright LC, et al. Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the 6-HZ psychomotor seizure model in the mice. Epilepsia. 2011;52(Suppl. 6):118\u20139.","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"16_CR12","first-page":"257","volume":"52","author":"A Pekcec","year":"2011","unstructured":"Pekcec A, Potschka H, Soares-da-Silva P. Effects of eslicarbazepine acetate and its metabolites in the corneal kindling model of epilepsy. Epilepsia. 2011;52(Suppl. 6):257.","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"16_CR13","first-page":"257","volume":"52","author":"J Soerensen","year":"2011","unstructured":"Soerensen J, Pekcec A, Potschka H, Soares-da-Silva P. The effects of eslicarbazepine acetate in the amygdala kindling model of temporal lobe epilepsy. Epilepsia. 2011;52(Suppl. 6):257.","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"16_CR14","first-page":"119","volume":"52","author":"G Sierra-Paredes","year":"2011","unstructured":"Sierra-Paredes G, Sierra-Marcuno G, Loureiro AI, Wright LC, Soares-da-Silva P. Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. Epilepsia. 2011;52(Suppl. 6):119.","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"16_CR15","first-page":"257","volume":"52","author":"S Hebeisen","year":"2011","unstructured":"Hebeisen S, Brady K, Konrad D, Soares-da-Silva P. Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels. Epilepsia. 2011;52(Suppl. 6):257\u20138.","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"16_CR16","first-page":"260","volume":"52","author":"K Brady","year":"2011","unstructured":"Brady K, Hebeisen S, Konrad D, Soares-da-Silva P. The effects of eslicarbazepine, R-licarbazepine, oxcarbazepine and carbamazepine on ion transmission Cav3.2 channels. Epilepsia. 2011;52(Suppl. 6):260.","journal-title":"Epilepsia"},{"unstructured":"Thiessen J. Bioavailability and bioequivalence. In: du Souich P, Orme M, Erill S, editors. The IUPHAR compendium of basic principles for pharmacological research in humans. IUPHAR; 2004. p. 55\u201366.","key":"16_CR17"},{"issue":"2","key":"16_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.25004\/IJPSDR.2011.030206","volume":"3","author":"D Shep","year":"2011","unstructured":"Shep D, Nimkar A, Shah R, Jaiswal V. Comparative bioavailability study with two sodium valproate tablet formulations in healthy subjects. Int J Pharma Sci Drug Res. 2011;3(2):101\u20133.","journal-title":"Int J Pharma Sci Drug Res"},{"issue":"8","key":"16_CR19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","volume":"44","author":"L Almeida","year":"2004","unstructured":"Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol. 2004;44(8):906\u201318.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"16_CR20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/0126839-200809060-00007","volume":"9","author":"C Fontes-Ribeiro","year":"2008","unstructured":"Fontes-Ribeiro C, Macedo T, Nunes T, Neta C, Vasconcelos T, Cerdeira R, et al. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D. 2008;9(6):447\u201354.","journal-title":"Drugs R D"},{"issue":"2","key":"16_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1011503032353","volume":"28","author":"SC Chow","year":"2001","unstructured":"Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001;28(2):155\u201369.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"16_CR22","first-page":"427","volume":"33","author":"VW Steinijans","year":"1995","unstructured":"Steinijans VW, Sauter R, Hauschke D, Diletti E, Schall R, Luus HG, et al. Reference tables for the intrasubject coefficient of variation in bioequivalence studies. Int J Clin Pharmacol Therapeut. 1995;33(8):427\u201330.","journal-title":"Int J Clin Pharmacol Therapeut"},{"key":"16_CR23","first-page":"819","volume":"48","author":"Y Hassan","year":"2007","unstructured":"Hassan Y, Alfadly S, Azmin M, Peh K, Tan T, Noorizan A, et al. Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers. Singap Med J. 2007;48:819\u201323.","journal-title":"Singap Med J"},{"issue":"4","key":"16_CR24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1208\/s12248-009-9142-z","volume":"11","author":"K Midha","year":"2009","unstructured":"Midha K, McKay G. Bioequivalence; its history, practice, and future. AAPS J. 2009;11(4):664\u201370.","journal-title":"AAPS J"},{"issue":"4","key":"16_CR25","first-page":"209","volume":"36","author":"S Rani","year":"2004","unstructured":"Rani S, Pargal A. Bioequivalence: an overview of statistical concepts. Indian J Pharmacol. 2004;36(4):209\u201316.","journal-title":"Indian J Pharmacol"},{"unstructured":"EMEA\/CPMP. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP\/EWP\/1401\/98, European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), 2001 [online]. Available from URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003011.pdf . Accessed 11 Apr 2011.","key":"16_CR26"},{"unstructured":"FDA\/CDER. Guidance for industry (draft). Food-effect bioavailability and fed bioequivalence studies. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2002 [online]. Available from URL: http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126833.pdf . Accessed 11 Apr 2011.","key":"16_CR27"},{"issue":"9","key":"16_CR28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","volume":"45","author":"L Almeida","year":"2005","unstructured":"Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45(9):1062\u20136.","journal-title":"J Clin Pharmacol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0016-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0016-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0016-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T10:09:34Z","timestamp":1746007774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0016-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,16]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0016-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2013,5,16]]}}}